[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicinova Inc (MNOV)

Medicinova Inc (MNOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 63,003
  • Shares Outstanding, K 49,221
  • Annual Sales, $ 410 K
  • Annual Income, $ -12,000 K
  • EBIT $ -13 M
  • EBITDA $ -13 M
  • 60-Month Beta 0.62
  • Price/Sales 152.47
  • Price/Cash Flow N/A
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 253.61% (+14.25%)
  • Historical Volatility 26.61%
  • IV Percentile 76%
  • IV Rank 30.32%
  • IV High 479.17% on 08/05/25
  • IV Low 155.47% on 02/13/26
  • Expected Move (DTE 6) 1.0625 (84.33%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 195
  • Open Int (30-Day) 110
  • Expected Range 0.1975 to 2.3225

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 1
  • High Estimate $-0.06
  • Low Estimate $-0.06
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2300 unch
on 06/12/26
1.4500 -15.17%
on 05/22/26
-0.1500 (-10.87%)
since 05/12/26
3-Month
1.2300 unch
on 06/12/26
1.5668 -21.50%
on 03/23/26
-0.1500 (-10.87%)
since 03/12/26
52-Week
1.1680 +5.31%
on 10/30/25
1.9600 -37.24%
on 10/31/25
-0.1500 (-10.87%)
since 06/12/25

Most Recent Stories

More News
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)
MediciNova: Q1 Earnings Snapshot

MediciNova: Q1 Earnings Snapshot

MNOV : 1.2300 (-3.91%)
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)
MediciNova to Participate at the 38th Annual ROTH Conference

LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)
MediciNova: Q4 Earnings Snapshot

MediciNova: Q4 Earnings Snapshot

MNOV : 1.2300 (-3.91%)
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)
2026 New Year’s Greetings from the CEO

LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code...

MNOV : 1.2300 (-3.91%)
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange...

MNOV : 1.2300 (-3.91%)

Business Summary

MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies,...

See More

Key Turning Points

3rd Resistance Point 1.3367
2nd Resistance Point 1.3133
1st Resistance Point 1.2967
Last Price 1.2300
1st Support Level 1.2567
2nd Support Level 1.2333
3rd Support Level 1.2167

See More

52-Week High 1.9600
Fibonacci 61.8% 1.6575
Fibonacci 50% 1.5640
Fibonacci 38.2% 1.4705
Last Price 1.2300
52-Week Low 1.1680

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.